Cambridge Healthtech Institute’s 9th Annual

Clinical Progress of Antibody-Drug Conjugates

Advancing Novel ADC Platforms and Combinations to the Clinic

April 11-12, 2019

 

Antibody-drug conjugates (ADCs) continue to emerge as a strong and promising strategy for target cancer therapy. Today, there are four ADCs approved and commercially available in the US, with another 175 investigational ADCs in development, from early discovery to clinical phase III trials, across both hematologic malignancies and solid tumor indications. Some of these trials are single-agent trials, while others are combinations. Companies are leveraging on lessons learned from first and second-generation trials to inform on next-generation ADC designs.

In this second installment of our 2-part ADC program, PEGS Boston’s 9th Annual Clinical Progress of Antibody-Drug Conjugates will invite investigators to share their latest results from preclinical and clinical trials, lessons learned to optimize clinical trial design, address toxicity concerns, and develop better predictability for translation from bench to clinic.

Preliminary Agenda

KEYNOTE PRESENTATION: The House of Vedotins

Bob Lechleider, PhD, SVP, Operations, Seattle Genetics

PRECLINICAL AND TRANSLATIONAL UPDATES

Single-Cell PK/PD of Antibody Drug Conjugates and Immuno-Oncology Agents to Design More Effective Therapies

Greg Thurber, PhD, Asst Prof, Chemical Engineering and Biomedical Engineering, University of Michigan

ADCs BEYOND ONCOLOGY

Developing Antibody Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant

Charlotte McDonagh, PhD, VP Biotherapeutics, Magenta Therapeutics

CLINICAL UPDATES

Targeting Breast Cancer with Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, Asst Prof, Medicine, Harvard Medical School

Overcoming Brentuximab Resistance with MDR1 Inhibitors

Robert W. Chen, MD, Asso Prof, Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center

Discovery of Next-Generation ADCs: Preclinical and Clinical Development of AVID100, an EGFR-Targeting ADC

Maureen O’Connor-McCourt, PhD, CSO, Forbius

The Right Agent for the Right Space - Clinical Development of An Anti-Epcam/Toxin Fusion Protein for the Treatment of Non-Muscle Invasive Bladder Cancer

Gregory P. Adams, PhD, CSO, Sesen Bio

IMPROVING THE SAFETY AND EFFICACY PROFILES OF ADCs

Improving the Efficacy and Safety Profile of A Recombinant Immunotoxin by Mitigating Immunogenicity with Tolerogenic Nanoparticles

Kei Kishimoto, PhD, CSO, Selecta Biosciences

Pre-Clinical Study of Liver Injury Induced By T-DM1: Molecular Mechanisms of T-DM1-Induced Hepatotoxicity

Wen Jin Wu, MD, PhD, Senior Investigator, OBP, CDER, FDA


* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean




Premier Sponsors


View By: